NIH's June 9 'America's Seed Fund Is Back' Webinar Reopens a Five-Year Window for Biomedical Small Business — and Signals a Sharper Foreign-Risk Posture in the Three-Part Series

At 1:30 p.m. ET on Tuesday, June 9, the National Institutes of Health will host the first session of a new "NIH Small Business 101" webinar series titled "America's Seed Fund Is Back — Powered by HHS." On paper, the event is an introductory program overview for new applicants to NIH's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. In context, it is something more deliberate: the formal restart of the largest single source of early-stage biomedical small-business funding in the federal government, following a multi-month suspension that began with the federal shutdown and continued through the reauthorization fight that produced the April 14 five-year extension.

The webinar series is structured as three sessions. June 9 covers program basics. July 14 covers budget construction. August 18 covers foreign risk. The sequencing is not arbitrary, and it is worth reading carefully — particularly the decision to dedicate a standalone session, at the third and final position in the series, to foreign-risk management. That is where the policy weight of the relaunch sits.

What the relaunch actually restored

The SBIR/STTR programs were originally established by the Small Business Innovation Development Act of 1982 and have been reauthorized at roughly five-year intervals since. The most recent reauthorization, signed into law on April 14, 2026, extended both programs for five years through 2031, restoring the statutory authority for federal agencies with extramural research-and-development budgets above $100 million to set aside a fixed percentage (3.2% for SBIR, 0.45% for STTR in FY26) for awards to qualified small businesses.

For NIH, the practical translation is that approximately $1.5 billion in FY26 biomedical small-business funding can now flow. The set-aside is not a discretionary appropriation; it is a statutory carve from the overall extramural research budget. When the reauthorization lapsed in early 2026, the set-aside lapsed with it, and the entire NIH small-business pipeline froze. The April 14 statutory restart unfroze it. The June 9 webinar is the operational restart — the moment NIH begins actively recruiting Phase I applicants under the new authority for the FY26 receipt dates running through the rest of the calendar year.

For biomedical small businesses, the financial significance is hard to overstate. NIH SBIR Phase I awards run up to $400,000 over six to twelve months, with Phase II awards up to $2 million over two years and Direct-to-Phase II awards available in qualified circumstances. Within the broader biomedical capital stack — where Series A rounds for early-stage therapeutics now routinely top $25 million but seed funding is harder to find than at any point in the past five years — the SBIR ladder is one of the only non-dilutive instruments that can fund preclinical work to the point of IND-enabling studies. The five-year reauthorization restores the policy stability that biotech founders and their advisors had been pricing as uncertain.

The June 9 session — what to expect

The "Small Business 101" framing signals an introductory posture, but the agenda is built around the operational changes that have accumulated since the previous NIH small-business orientation cycle. NIH's Seed Office has, over the past year, modified its program announcement structure, simplified some of the Phase I budget templates, and updated its review-criteria language to emphasize commercialization potential. New applicants and returning applicants both need to walk through the changes.

The session is anchored by NIH Small Business experts and includes live Q&A. For applicants planning to submit against the September 5 standard SBIR receipt date — the next major NIH small-business deadline — the June 9 webinar is the most efficient way to surface program-officer expectations on commercialization plans, study sections, and the new program-announcement structure before the summer drafting window closes. The webinar will be recorded and made available subsequently, but the live Q&A is where the operational nuance lives.

The July 14 budget session — the quiet substance shift

The second session, "Building Your Budget" on July 14, will look familiar to anyone who has built an SBIR Phase I budget in the past, but the content sits inside a changed indirect-cost environment. The OMB Uniform Guidance rewrite published May 29 — with comments due July 13, the day before the budget webinar — contains provisions that will affect cost allowability across federal grants beginning October 1, 2026. NIH SBIR applicants whose Phase I awards are issued after October 1 will be operating under the new cost principles. Phase II applicants whose budgets are being constructed now for receipt dates later in the year will need to model both regimes.

The substantive shifts that matter for SBIR budgets include the tightened restrictions on advertising and public-relations costs under proposed §200.421, the broader limits on conferences and meetings, and the formalization of lobbying-cost prohibitions. None of these are first-impression issues for SBIR — Phase I budgets are largely concentrated in direct labor, contracted research, and supplies — but Phase II budgets that include workshop costs, advisory-board meetings, or any communications work to surface preliminary results face exposure to the new cost-allowability framework. The July 14 webinar will not relitigate the OMB rule, but the budget templates and program-officer guidance will reflect its anticipated implementation.

The August 18 foreign-risk session — the load-bearing signal

The third and final session, "Managing Foreign Risk" on August 18, is where the policy weight of the relaunch concentrates. NIH dedicating a standalone webinar to foreign risk in an introductory small-business series is itself a signal — historical Small Business 101-style orientations rarely treated foreign-risk management as a co-equal topic with budget construction. The decision to place it at the end of the sequence, after applicants have absorbed program basics and budget mechanics, reads as a deliberate front-loading of the substantive expectation: that any biomedical small business engaging with NIH SBIR/STTR funding under the new authority will be screened against an expanded set of foreign-affiliation criteria.

The screening framework draws from three layered policy sources. First, the SBIR reauthorization itself, which extended and strengthened foreign-affiliation due-diligence requirements first enacted in the 2022 reauthorization (the "due diligence" provisions on foreign country of concern relationships). Second, the OMB May 29 proposed rule, which inserts a new §200.220 prohibiting use of federal funds for collaboration with covered foreign countries and entities — a provision that will apply to NIH SBIR awards if finalized as proposed. Third, NIH's own institute-level guidance, which has tightened reporting requirements on foreign components, foreign affiliations of senior personnel, and foreign sub-recipients of federal awards.

For biomedical small businesses, the practical exposure points are: foreign-national senior personnel (particularly principal investigators with current or recent affiliations to entities in covered countries), foreign sub-contractors providing study services (CROs, manufacturing partners, animal-model providers), and foreign equity ownership of the applicant entity. The reauthorized SBIR statute and the proposed OMB rule both expand the scope of these disclosures and the consequences of inadequate disclosure. The August 18 webinar will, by all indications, walk applicants through the new disclosure architecture and the operational steps to surface and document foreign affiliations before they become award-blocking issues.

The strategic implication for biomedical small businesses is to treat foreign-risk diligence as a Phase I preparation step, not a Phase II compliance step. Founders who are uncertain whether a particular advisor relationship, contract research relationship, or capital structure triggers disclosure should resolve the question before the September 5 receipt date, not after. The August 18 webinar is the briefing for that work; the September 5 deadline is the moment it has to be done.

What the relaunch does not restore

Two things the relaunch does not restore are worth flagging explicitly.

First, the relaunch does not restore the political environment under which NIH SBIR awards were previously made. The OMB §200.205 pre-issuance review provision, if finalized, would apply to NIH discretionary grants — including SBIR awards — issued after October 1, 2026. The five-year statutory authority is restored, but the operational pipeline for the back half of FY27 and beyond will run through a political pre-issuance review layer that did not exist before. Biomedical small businesses with research programs that intersect politically sensitive areas (gain-of-function research, certain genomic technologies, gender-related health research) need to model that exposure.

Second, the relaunch does not restore the prior cadence of NIH program-announcement turnover. NIH is in the middle of a substantial restructuring of its SBIR program-announcement portfolio, simplifying topic structure and emphasizing investigator-initiated science over highly-prescriptive solicitations. This is, on balance, a welcome direction for applicants — broader topic latitude generally favors small companies whose scientific direction is set by their founders rather than by federal program managers — but it means the FY27 announcement landscape will look different from the FY24/FY25 landscape that most repeat applicants are familiar with.

The action window

For NIH SBIR applicants targeting the September 5 standard receipt date, the operational sequence is straightforward. Register for the June 9 webinar this week. Use the recording (if missed live) to update internal applicant guidance documents. Build Phase I budgets in July using the templates that will be discussed on July 14, with attention to the October 1 cost-principle transition for Phase II projection. Complete the foreign-risk diligence by mid-August so the August 18 webinar reinforces rather than reveals exposure. Submit by September 5.

The five-year reauthorization is the runway. The June 9 webinar is the runway lights coming on. The companies that capitalize on the relaunch will be the ones treating it as the start of a structured submission cycle rather than as a one-off opportunity to file a Phase I and hope.

For ongoing coverage of NIH SBIR opportunities and biomedical small-business policy, see Granted News.